Methyl-(2-propyl-pentyl)-amine | 53214-37-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Methyl-(2-propyl-pentyl)-amine
• 英文别名: Methyl(2-propylpentyl)amine；N-methyl-2-propylpentan-1-amine
• CAS: 53214-37-2
• 化学式: C₉H₂₁N
• 分子量: 143.272
• InChiKey: SAJJHUHPHXDIJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-甲基-2-丙基戊酰胺 生成 Methyl-(2-propyl-pentyl)-amine
  参考文献：
  名称：

  Benoit Guyod; Benoit Guyod; Simiand, European Journal of Medicinal Chemistry, 1974, vol. 9, # 2, p. 169 - 174

  摘要：

  DOI：

文献信息

• Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1935887A1

  公开（公告）日：2008-06-25

  The invention relates to heterocyclic substituted carbonyl derivatives of the formula I that display selective binding to dopamine D3 receptors and are useful for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

  本发明涉及式 I 的杂环取代的羰基衍生物 本发明涉及式 I 的杂环取代羰基衍生物，该衍生物与多巴胺 D3 受体具有选择性结合，可用于治疗需要此类治疗的患者中与多巴胺 D3 受体活性相关的中枢神经系统紊乱，包括向受试者施用治疗有效量的所述化合物以缓解此类紊乱。可用这些化合物治疗的中枢神经系统疾病包括精神障碍、药物依赖、药物滥用、运动障碍（如帕金森病、帕金森氏症、神经抑制剂诱发的迟发性运动障碍、吉勒-德拉图雷特综合征和亨廷顿氏病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及本文所述化合物的制备过程以及将这些化合物用作多巴胺 D3 受体成像剂的制备和使用方法。
• ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1940401B1

  公开（公告）日：2012-07-11
• Organic-Inorganic Hybrid Perovskites, Devices, and Methods
  申请人：Florida State University Research Foundation, Inc.

  公开号：US20180037813A1

  公开（公告）日：2018-02-08

  Provided herein are organic-inorganic hybrid-perovskites, including metal halide perovskites having a 1D crystal structure. The metal halide perovskites may be luminescent. The metal halide perovskites may include a dopant, including an emitter dopant. Methods of forming metal halide perovskites, and devices including the metal halide perovskites also are provided.
• Methods of Making Metal Halide Perovskites
  申请人：Florida State University Research Foundation, Inc.

  公开号：US20180127443A1

  公开（公告）日：2018-05-10

  Provided herein are methods of making metal halide perovskites, including methods of making bulk crystals or micro crystals. The metal halide perovskites may be a light emitting material.
• US8772301B2
  申请人：——

  公开号：US8772301B2

  公开（公告）日：2014-07-08